Abstract
The US generics market was estimated at US$18.1 billion in 2004; the leading
European generics markets together totalled between US$10--US$11 billion for
the same period. This new report asks why there is such a difference in value?
Contrasts in regulatory systems, legislative background and market
characteristics increase the difficulties for companies from one area who are
trying to enter another market. US and European Prescription Generic Markets
reviews these divergent characteristics and also looks at those areas where
the two sides are moving closer together.
One major finding that emerges from this analysis is the surprising absence of
the majority of US domestic generic companies from overseas markets. The
report contrasts this with the increasing presence of foreign generic
companies in the US, looks at where these new competitors have come from and
assesses how much of a threat they represent to the major US companies.
US and European Prescription Generic Markets provides an in-depth examination
of:
- Successful generic growth strategies and how they vary
- Defensive tactics of the multinationals
- Generic industry growth prospects and possible threats
- A history of the generic markets
- The legislative and regulatory background
- How differences between the US and European markets have developed
- Who are the major players and how they rose to the top
Who should buy this report?
- Generic companies interested in understanding the opportunities and
challenges in the American and European markets.
- Pharma/biotech companies with branded products in these markets, in order
to identify threats and learn of defense strategies.
- For US companies considering a venture into Europe, it is an invaluable
tool for formulating a suitable strategy.
- For European or other non-US companies that are looking at opportunities
in the US, the report provides a concise summary of the legal, regulatory and
commercial issues that they will need to address.
| 
View Cart
